Pinto JA, et al. - As a part of this trial, researchers intended to elucidate the drug exposure/safety of lopinavir/ritonavir using World Health Organization (WHO) weight band dosing of antiretrovirals in human immunodeficiency virus–infected children. Adequate LPV plasma exposure was achieved due to the WHO weight band dosing guidelines in children. Nevertheless, it appeared to be higher than that expected with Food and Drug Administration dosing guidelines. The treatment was found to be well tolerated, with favorable 24-week efficacy data, regardless of the higher LPV exposure.